What the bad jobs report means for markets
On Tuesday, Needham analyst Alan Carr adjusted the price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) stock, lifting it to $66.00 from the previous $64.00, while reiterating a Buy rating. Currently trading at $52.34, RYTM has attracted significant analyst attention, with targets ranging from $60 to $94. According to InvestingPro data, 4 analysts have recently revised their earnings expectations upward. The revision reflects positive anticipation of the upcoming Phase 3 trial results for setmelanotide, a treatment for Hypothalamic Obesity (HO).
Carr anticipates that the trial’s topline data, expected in the first half of 2025 and likely in April, will serve as a significant catalyst for Rhythm Pharmaceuticals’ stock. The company, currently valued at $3.31 billion, maintains impressive gross profit margins of 89.73%. The optimism is based on a thorough review of the drug’s clinical data in HO and recent feedback from key opinion leaders (KOLs). For deeper insights into RYTM’s financial health and growth potential, InvestingPro subscribers can access comprehensive analysis and 8 additional expert tips.
In what Carr describes as the "most likely scenario," there is a 50% probability of success (POS) that setmelanotide will achieve a 15-20% placebo-adjusted reduction in Body Mass Index (BMI), which is the primary endpoint of the trial. With a beta of 2.3, RYTM shows higher volatility than the broader market, suggesting significant potential price movements around key catalysts. This outcome is projected to provide a more than 20% increase in the value of Rhythm Pharmaceuticals’ shares.
The analyst’s confidence in the drug’s forthcoming results is bolstered by the positive KOL feedback and the data reviewed thus far. Rhythm Pharmaceuticals is focused on the development of therapies for rare genetic disorders of obesity, and setmelanotide is their leading candidate.
The company’s stock is expected to respond to the release of the Phase 3 trial data, which is being closely monitored by investors and industry observers. Rhythm Pharmaceuticals continues to progress in its efforts to address unmet medical needs within the field of obesity treatment.
In other recent news, Rhythm Pharmaceuticals has been the focus of several analyst evaluations and updates on its drug development efforts. Stifel analysts reiterated a Buy rating with a $78 target, emphasizing the potential of the phase 3 clinical trial results for setmelanotide in treating hypothalamic obesity (HO), with an anticipated release in the second quarter of 2025. Citizens JMP also maintained a Market Outperform rating, with an $81 target, highlighting setmelanotide’s effectiveness in conditions related to MC4R pathway dysfunction and its established safety profile. Raymond (NSE:RYMD) James reaffirmed an Outperform rating and an $80 target, noting the importance of upcoming Phase III data and expressing confidence in setmelanotide’s efficacy potential.
Additionally, H.C. Wainwright adjusted its price target for Rhythm Pharmaceuticals to $70, maintaining a Buy rating. The firm pointed out the significance of upcoming clinical milestones, including the initiation of patient enrollment for various trials and the importance of the Phase 3 HO data readout. These developments suggest a positive outlook for Rhythm Pharmaceuticals, with analysts from different firms expressing optimism about the company’s strategic direction and drug pipeline. The focus remains on setmelanotide’s market potential and the broader implications for Rhythm Pharmaceuticals’ financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.